Index reshuffle shifts Doximity into value and defensive territory

Doximity (DOCS) has just been dropped from several Russell growth benchmarks and added to a range of value and value defensive indices, including the Russell 1000 Value and Russell Midcap Value.

This reclassification changes how index providers bucket the stock and can influence investor flows. It can also make this an important moment to reassess how Doximity fits within a portfolio focused on growth, value, or income stability.

Doximity’s short term momentum has picked up, with a 1 day share price return of 4.57% and 30 day share price return of 11.02%. However, the total shareholder return over the past year has fallen 62.44%, so recent index moves come against a backdrop of longer term share price and total return weakness.

If you are reassessing Doximity after this index reshuffle, it can also be useful to see how other healthcare technology stocks are trading by scanning 40 healthcare AI stocks.

Doximity now trades below several fair value estimates and sits at a discount to analyst targets after a sharp reset in expectations. Is the market being too cautious, or simply pricing execution and governance risks correctly?

Most Popular Narrative: 32.2% Undervalued

The most followed narrative on Doximity frames a fair value of $33.70 against the last close of $22.86, creating a wide gap that investors may want to understand before reacting to the index shift.

What I like about Doximity is that there really is a very high viewership / user base of active practicing Physicians in the US and that is not invaluable and definitely could be monetized perhaps more efficiently. I also think that Doximity offers a lot of interesting tools for Physicians a lot of which you’re free and really marketed towards I think Physicians who are more in private practice. It’s a little bit unclear how much value that provides given that most Physicians and practitioners these days are employed and not a private practice.

The narrative, according to Dc12, focuses on Doximity’s physician reach and product usage, and then layers in assumptions on growth, margins and valuation multiples that the market is currently discounting. Want to see how those building blocks stack together and what has to go right for that $33.70 figure to hold up? The full narrative describes the revenue runway, profitability profile and the type of earnings multiple it expects Doximity to support over time.

Result: Fair Value of $33.70 (UNDERVALUED)

However, Doximity’s narrative can be shaken if physician engagement softens or if its AI tools lose ground to competing platforms that capture clinician attention.

Next Steps

If this mix of cautious questions and pockets of optimism around Doximity resonates with you, consider promptly reviewing the underlying data yourself and weighing the potential rewards highlighted in our 2 key rewards

Looking for more investment ideas beyond Doximity?

If Doximity has sharpened your thinking, do not stop there. Use the Simply Wall Street Screener to spot fresh opportunities that fit your style.

• Target potential mispricings by scanning 41 high quality undervalued stocks that pair earnings quality with prices that some investors may be overlooking.
• Build a more predictable income stream by reviewing 8 dividend fortresses that focus on higher yields and balance sheet support.
• Aim for steadier portfolio behavior by checking 74 resilient stocks with low risk scores that screen for resilience and lower risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.